Literature DB >> 16038481

Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1.

Mina John1, Corey B Moore, Ian R James, Simon A Mallal.   

Abstract

HIV-specific cytotoxic T lymphocyte (CTL) responses mediated by human leukocyte antigen (HLA) recognition and antiretroviral drugs exert selection pressure on HIV-1 in vivo. The selection of CTL escape mutations strongly underpins the failure of CTL control in most untreated infections whilst drug-resistance mutations predict failure of drug control. These two evolutionary forces share common target residues in HIV-1 at which their selection effects could be synergistic or antagonistic, such that the propensity to develop drug resistance and virological treatment failure may be influenced by HLA type. We examined HIV-1 reverse transcriptase (RT) and protease sequences in a large clinical observational cohort of 487 HIV-infected individuals and found evidence of site-specific interactions between specific antiretroviral drug exposures, HLA alleles and HIV sequence diversity at population level. Such interactions may have general and specific implications for explaining in vivo/in vitro discordance of drug resistance, host-specific susceptibility to drug resistance, individualization of therapy and therapeutic vaccine design.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16038481

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  17 in total

1.  Dual selection pressure by drugs and HLA class I-restricted immune responses on human immunodeficiency virus type 1 protease.

Authors:  Sandra M Mueller; Birgit Schaetz; Kathrin Eismann; Silke Bergmann; Michael Bauerle; Matthias Schmitt-Haendle; Hauke Walter; Barbara Schmidt; Klaus Korn; Heinrich Sticht; Bernd Spriewald; Ellen G Harrer; Thomas Harrer
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

2.  Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.

Authors:  Zixin Hu; Françoise Giguel; Hiroyu Hatano; Patrick Reid; Jing Lu; Daniel R Kuritzkes
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors.

Authors:  Valentina Svicher; Tobias Sing; Maria Mercedes Santoro; Federica Forbici; Fátima Rodríguez-Barrios; Ada Bertoli; Niko Beerenwinkel; Maria Concetta Bellocchi; Federigo Gago; Antonella d'Arminio Monforte; Andrea Antinori; Thomas Lengauer; Francesca Ceccherini-Silberstein; Carlo Federico Perno
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  Selective pressures of HLA genotypes and antiviral therapy on human immunodeficiency virus type 1 sequence mutation at a population level.

Authors:  Golo Ahlenstiel; Kirsten Roomp; Martin Däumer; Jacob Nattermann; Martin Vogel; Jürgen K Rockstroh; Niko Beerenwinkel; Rolf Kaiser; Hans-Dieter Nischalke; Tilman Sauerbruch; Thomas Lengauer; Ulrich Spengler
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

5.  Protease polymorphisms in HIV-1 subtype CRF01_AE represent selection by antiretroviral therapy and host immune pressure.

Authors:  Weerawat Manosuthi; David M Butler; Josué Pérez-Santiago; Art Fy Poon; Satish K Pillai; Sanjay R Mehta; Mary E Pacold; Douglas D Richman; Sergei Kosakovsky Pond; Davey M Smith
Journal:  AIDS       Date:  2010-01-28       Impact factor: 4.177

6.  Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239.

Authors:  Panagiotis Vagenas; Vennansha G Williams; Michael Piatak; Julian W Bess; Jeffrey D Lifson; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12-01       Impact factor: 3.731

7.  Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.

Authors:  Maria Carmen Puertas; Maria Jose Buzón; Anna Artese; Stefano Alcaro; Luis Menendez-Arias; Carlo Federico Perno; Bonaventura Clotet; Francesca Ceccherini-Silberstein; Javier Martinez-Picado
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

8.  Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance.

Authors:  Monika Tschochner; Abha Chopra; Tanya M Maiden; Imran F Ahmad; Ian James; Hansjakob Furrer; Huldrych F Günthard; Simon Mallal; Andri Rauch; Mina John
Journal:  Antivir Ther       Date:  2009

9.  Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.

Authors:  Tanya L Applegate; Silvana Gaudieri; Anne Plauzolles; Abha Chopra; Jason Grebely; Michaela Lucas; Margaret Hellard; Fabio Luciani; Gregory J Dore; Gail V Matthews
Journal:  Antivir Ther       Date:  2014-08-08

10.  Do HIV-specific CTL continue to have an antiviral function during antiretroviral therapy? If not, why not, and what can be done about it?

Authors:  Dorian McIlroy
Journal:  Front Immunol       Date:  2013-03-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.